|
EP3489360A3
(en)
|
2010-07-19 |
2019-08-28 |
Ionis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
AU2011325956B2
(en)
|
2010-11-12 |
2016-07-14 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
AU2013262709A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
KR20150030205A
(ko)
|
2012-05-16 |
2015-03-19 |
라나 테라퓨틱스, 인크. |
Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
|
|
EA201492121A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии семейства генов гемоглобина
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
JP2015523853A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Ａｔｐ２ａ２発現を調節するための組成物及び方法
|
|
SG11201407486PA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating utrn expression
|
|
WO2014210097A2
(en)
*
|
2013-06-26 |
2014-12-31 |
Novartis Animal Health Us. Inc. |
Markers to predict macrocyclic lactone drug resistance in dirofilaria immitis, the causative agent of heartworm disease
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
KR102275504B1
(ko)
*
|
2013-09-05 |
2021-07-09 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함
|
|
JP2016534035A
(ja)
|
2013-10-04 |
2016-11-04 |
ラナ セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症を治療するための組成物及び方法
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
CN116970607A
(zh)
|
2014-03-19 |
2023-10-31 |
Ionis制药公司 |
用于调节共济失调蛋白2表达的组合物
|
|
MY192634A
(en)
|
2014-04-01 |
2022-08-29 |
Biogen Ma Inc |
Compositions for modulating sod-1 expression
|
|
EP3207138B1
(en)
*
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
US10858650B2
(en)
|
2014-10-30 |
2020-12-08 |
The General Hospital Corporation |
Methods for modulating ATRX-dependent gene repression
|
|
WO2016112132A1
(en)
*
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
US10426789B2
(en)
|
2015-02-26 |
2019-10-01 |
Ionis Pharmaceuticals, Inc. |
Allele specific modulators of P23H rhodopsin
|
|
GB201504124D0
(en)
|
2015-03-11 |
2015-04-22 |
Proqr Therapeutics B V |
Oligonucleotides
|
|
WO2016149455A2
(en)
|
2015-03-17 |
2016-09-22 |
The General Hospital Corporation |
The rna interactome of polycomb repressive complex 1 (prc1)
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
US10801024B2
(en)
*
|
2015-05-20 |
2020-10-13 |
Indiana University Research And Technology Corporation |
Inhibition of lncRNA HOTAIR and related materials and methods
|
|
EP3124619B1
(en)
*
|
2015-07-31 |
2019-03-06 |
Menicon Co., Ltd |
Reagents, method and kit for across and within dog breed glaucoma diagnosis
|
|
JP2018538287A
(ja)
*
|
2015-12-14 |
2018-12-27 |
コールド スプリング ハーバー ラボラトリー |
多発性嚢胞腎の処置のためのアンチセンスオリゴマー
|
|
CA3006015A1
(en)
|
2015-12-31 |
2017-07-06 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
JP6853193B2
(ja)
|
2016-01-29 |
2021-03-31 |
協和キリン株式会社 |
核酸複合体
|
|
WO2017134252A1
(en)
*
|
2016-02-05 |
2017-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides effective to reduce the expression of menin in cancer cells of a subject
|
|
MY200252A
(en)
|
2016-04-18 |
2023-12-16 |
Sarepta Therapeutics Inc |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
CN109477097A
(zh)
|
2016-04-20 |
2019-03-15 |
Jbs科学公司 |
检测CTNNBl和HTERT突变的试剂盒和方法及其在HCC检测和疾病管理中的用途
|
|
CA3023514A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
EP3498724B1
(en)
|
2016-06-30 |
2023-06-21 |
Kyowa Kirin Co., Ltd. |
Nucleic acid complex
|
|
EP3478839A1
(en)
|
2016-07-01 |
2019-05-08 |
H. Hoffnabb-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
US11655470B2
(en)
*
|
2016-07-05 |
2023-05-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Diagnosing COL6-related disorders and methods for treating same
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
US11118182B2
(en)
|
2016-11-17 |
2021-09-14 |
Ramot At Tel-Aviv University Ltd. |
Modulators of human KAI1 metastasis suppressor gene, methods and uses thereof
|
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
|
US11352625B2
(en)
|
2017-01-12 |
2022-06-07 |
Duke University |
Compositions and methods for disrupting the molecular mechanisms associated with mitochondrial dysfunction and neurodegenerative disease
|
|
WO2018180005A1
(ja)
*
|
2017-03-31 |
2018-10-04 |
国立研究開発法人日本医療研究開発機構 |
コンドロイチン硫酸生合成を阻害するアンチセンス核酸
|
|
GB201706009D0
(en)
*
|
2017-04-13 |
2017-05-31 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of stargardt disease
|
|
US20190055564A1
(en)
*
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
EP4219715A3
(en)
|
2017-09-08 |
2023-09-06 |
MiNA Therapeutics Limited |
Stabilized cebpa sarna compositions and methods of use
|
|
CA3075205A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
Stabilized hnf4a sarna compositions and methods of use
|
|
US20230201357A1
(en)
*
|
2017-11-08 |
2023-06-29 |
Aptamer Diagnostic, Inc. |
D-dimer-specific aptamers and methods of use in diagnostics, therapeutic and theranostic purposes
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
WO2019109001A1
(en)
*
|
2017-12-01 |
2019-06-06 |
The Texas A&M University System |
Angelman syndrome antisense treatment
|
|
RU2020125769A
(ru)
*
|
2018-02-09 |
2022-03-10 |
Дженентек, Инк. |
Олигонуклеотиды для модуляции экспрессии tmem106b
|
|
CA3091789A1
(en)
*
|
2018-02-21 |
2019-08-29 |
Bristol-Myers Squibb Company |
Camk2d antisense oligonucleotides and uses thereof
|
|
US11732260B2
(en)
|
2018-03-02 |
2023-08-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-β precursor protein
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
CA3094020A1
(en)
|
2018-04-11 |
2019-10-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of ezh2 expression
|
|
SG11202010215TA
(en)
|
2018-05-09 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing atxn3 expression
|
|
TWI851574B
(zh)
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
|
|
WO2020007772A1
(en)
*
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
WO2020007700A1
(en)
*
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
WO2020011653A1
(en)
*
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
EP3824086A1
(en)
*
|
2018-07-19 |
2021-05-26 |
Stichting Katholieke Universiteit |
Antisense oligonucleotides rescue aberrant splicing of abca4
|
|
CA3106986A1
(en)
|
2018-07-25 |
2020-01-30 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn2 expression
|
|
CN112912112B
(zh)
*
|
2018-10-26 |
2024-12-17 |
Vrije布鲁塞尔大学 |
肝特异性核酸调节元件以及其方法及用途
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
MX2021008918A
(es)
|
2019-01-31 |
2021-08-24 |
Ionis Pharmaceuticals Inc |
Moduladores de expresion yap1.
|
|
AU2020239987A1
(en)
*
|
2019-03-15 |
2021-11-04 |
University Of Massachusetts |
Oligonucleotides for tissue specific ApoE modulation
|
|
CA3135180A1
(en)
|
2019-03-29 |
2020-10-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating ube3a-ats
|
|
US11739324B2
(en)
|
2019-06-25 |
2023-08-29 |
Stichting Katholieke Universiteit |
Antisense oligonucleotides rescue aberrant splicing of ABCA4
|
|
EP4017539A1
(en)
|
2019-08-19 |
2022-06-29 |
MiNA Therapeutics Limited |
Oligonucleotide conjugate compositions and methods of use
|
|
US20220290147A1
(en)
*
|
2019-08-30 |
2022-09-15 |
Baylor College Of Medicine |
System for regulating gene expression
|
|
EP3822370A1
(en)
*
|
2019-11-15 |
2021-05-19 |
Curiosity Diagnostics Sp. z o.o. |
Method of determining the presence of a hyper-virulent clostridioides difficile strain of the b1/nap1/027 group in a sample
|
|
WO2021126997A1
(en)
*
|
2019-12-18 |
2021-06-24 |
Petdx, Inc. |
Methods and compositions for cancer detection, characterization or management in companion animals
|
|
US20230127437A1
(en)
*
|
2020-01-31 |
2023-04-27 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Antisense oligonucleotide of atn1
|
|
WO2021163281A1
(en)
*
|
2020-02-12 |
2021-08-19 |
Accutar Biotechnology Inc. |
Antisense oligonucleotides and their use for treating pendred syndrome
|
|
JPWO2021177418A1
(enExample)
*
|
2020-03-04 |
2021-09-10 |
|
|
|
WO2021222654A1
(en)
*
|
2020-04-29 |
2021-11-04 |
Saliogen Therapeutics, Inc. |
Compositions and methods for treatment of inherited macular degeneration
|
|
IL298530A
(en)
|
2020-06-29 |
2023-01-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating plp1
|
|
BR112023000988A2
(pt)
*
|
2020-07-22 |
2023-03-28 |
The Florey Inst Of Neuroscience And Mental Health |
Composições e métodos para o tratamento de distúrbios associados a mutações de perda de função em scn2a
|
|
KR20230043914A
(ko)
|
2020-07-28 |
2023-03-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
App 발현을 감소시키기 위한 화합물 및 방법
|
|
WO2022032017A2
(en)
*
|
2020-08-07 |
2022-02-10 |
The General Hospital Corporation |
Human xist antisense oligonucleotides for x reactivation therapy
|
|
EP4015040A1
(en)
*
|
2020-12-16 |
2022-06-22 |
Fundación para la Formación e Investigación Sanitarias de la Región de Murcia |
Method for treating blood diseases
|
|
US12018261B2
(en)
|
2020-12-18 |
2024-06-25 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating factor XII
|
|
US20220370599A1
(en)
*
|
2021-04-30 |
2022-11-24 |
Greenlight Biosciences, Inc. |
Messenger rna therapeutics and compositions
|
|
EP4355759A4
(en)
|
2021-06-18 |
2026-05-13 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF IFNAR1
|
|
MX2024000996A
(es)
|
2021-07-21 |
2024-06-28 |
AcuraStem Incorporated |
Oligonucleótido antisentido unc13a.
|
|
US11833221B2
(en)
|
2021-09-01 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds for reducing DMPK expression
|
|
CN118541484A
(zh)
*
|
2021-12-17 |
2024-08-23 |
豪夫迈·罗氏有限公司 |
反义寡核苷酸
|
|
WO2023139360A1
(en)
*
|
2022-01-19 |
2023-07-27 |
Autolus Limited |
Nucleic acid construct
|
|
EP4590841A2
(en)
*
|
2022-09-20 |
2025-07-30 |
Aldevron, LLC |
Best1 vectors and uses thereof
|
|
UY40699A
(es)
|
2023-04-05 |
2024-08-30 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de pln
|
|
GB202312098D0
(en)
*
|
2023-08-08 |
2023-09-20 |
Ucl Business Ltd |
Therapeutic molecules
|
|
AU2024339330A1
(en)
*
|
2023-09-13 |
2026-04-02 |
Haya Therapeutics Sa |
Compositions and methods for modulating wisp2 super-enhancer-associated rna
|
|
WO2025072672A2
(en)
*
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Slc6a19-targeting modulatory nucleic acid agents
|
|
GB202401412D0
(en)
*
|
2024-02-02 |
2024-03-20 |
Harness Therapeutics Ltd |
Functional nucleic acid
|
|
WO2026033502A1
(en)
*
|
2024-08-09 |
2026-02-12 |
Associação Biopolis |
Kit, method, and uses thereof
|
|
WO2026074434A1
(en)
*
|
2024-10-01 |
2026-04-09 |
Fondazione Istituto Italiano Di Tecnologia |
Rad51/brca2 complex aptamers and uses thereof
|